RenovoRx Inc. (RNXT)
NASDAQ: RNXTHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
RNXT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $60.02M
- EPS (TTM)
- -$0.31
- Dividend yield
- None
- 52-week range
- 0.701 – 2.59
- Day range
- 1.31 – 1.37
- Volume / Avg
- 438.65K / 761.09K
- Beta
- —
- Shares outstanding
- 45.13M
- Next earnings
- Nov 9, 2026
52-week range
RNXT stock today
RenovoRx (RNXT) closed at $1.33 on Oct 8, down 2.92% (-$0.04), versus the S&P 500's 0.47% decline. At this level, RNXT sits in the middle of its 52-week range of $0.701 to $2.59: 48.6% below the high, set on Sep 2, 2026 and 89.7% above the low. RNXT is up 58.3% year to date, outperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has gained 9.9%.
RenovoRx has posted a net loss over the last twelve months (EPS of -$0.31), so its P/E ratio is not meaningful. RenovoRx's next earnings report is expected on Nov 9, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About RenovoRx
Company profileRenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Shaun R. Bagai
- Headquarters
- Mountain View, CA
- Employees
- 17
- IPO year
- 2021
- Website
- renovorx.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$7.13+436.09%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 9, 2026
RNXT news
All RNXT newsRenovoRx peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MREOMereo BioPharma Group plc ADR | 0.3752 | +6.35% | $59.92M | vs RNXT |
| GOSSGossamer Bio Inc. | 9.88 | -2.95% | $60.43M | vs RNXT |
| KLRSKalaris Therapeutics Inc. | 2.50 | -2.34% | $59.51M | vs RNXT |
| XLOXilio Therapeutics Inc. | 9.01 | 0.00% | $59.29M | vs RNXT |
| IBIOiBio Inc. | 0.92 | -8.91% | $59.16M | vs RNXT |
| ELOXEloxx Pharmaceuticals Inc. | 15.18 | +2.02% | $61.27M | vs RNXT |
| BOLDBoundless Bio Inc. | 2.58 | -2.27% | $58.69M | vs RNXT |
| PLRXPliant Therapeutics Inc. | 1.00 | +1.01% | $61.92M | vs RNXT |
Indexes, lists and sector
Appears in lists
RenovoRx stock FAQ
What is RenovoRx's stock price today?
RNXT last traded at $1.33 as of Oct 8, 4:00 PM EDT, down 2.92% on the day. Prices are delayed at least 15 minutes.
When is RenovoRx's next earnings date?
RenovoRx is expected to report earnings on Monday, November 9, 2026.
Who is RenovoRx's CEO?
Mr. Shaun R. Bagai is the chief executive officer of RenovoRx Inc., which has about 17 employees.
What is the RNXT 52-week high?
The 52-week high for RNXT is $2.59 and the 52-week low is $0.701. The stock is currently 48.6% below its high.